|Study Description:||The goal of this clinical research study is to learn if Revlimid® |
(lenalidomide) when given with rituximab can help to control FL and also
increase the length of the disease response. This will be compared with the
current standard of care, which is rituximab plus chemotherapy.
Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells. FL blocks the immune
system's ability to attack and kill tumor cells. Lenalidomide has been shown
to restore the immune cells’ ability to attack and kill tumor cells.
Researchers want to find out if adding lenalidomide can restore the immune
system's defenses against tumor cells, while treating the disease at the same
Rituximab is designed to attach to cancer cells and damage them, which may
cause the cancer cells to die. It is also designed to cause the immune system
to attack cancer cells.